Brain atrophy: screening
QuibimProduct specifications |
Information source:
Vendor
Last updated: Feb. 11, 2022 |
General | |
---|---|
Product name | Brain atrophy: screening |
Company | Quibim |
Subspeciality | Neuro |
Modality | MR |
Disease targeted | Alzheimer's, Multiple sclerosis, Parkinson’s disease, Epilepsy, Amyotrophic lateral sclerosis (ALS) |
Key-features | Volume of grey matter, white matter, cerebrospinal fluid and their distribution, parenchyma fraction |
Suggested use | Without interference of a radiologist: AI-only diagnosis |
Data characteristics | |
Population | Patients with neurological degenerative disease |
Input | MRI T1 GRE 3D T1 Fast Gradient Echo |
Input format | |
Output | One-page structured report: normative bars of brain (sub)region volume |
Output format | DICOM Secondary Capture / PDF |
Technology | |
Integration | Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution |
Trigger for analysis | Automatically, right after the image acquisition |
Processing time | > 10 minutes |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
No or not yet |
Market presence | |
On market since | 01-2019 |
Distribution channels | |
Countries present (clinical, non-research use) | 8 |
Paying clinical customers (institutes) | 5+ |
Research/test users (institutes) | <5 |
Pricing | |
Pricing model | License |
Based on | Number of installations, Number of analyses |
Evidence | |
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance | |
Other relevant papers | Magraner MJ, Bosca I, Simó-Castello M, García-Martí G, Alberich-Bayarri A, Álvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B (2012). Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012 Jan; 54(1): 5-12. |